Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 287 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Redwood City, California Clear all
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

NCT00878709
View directory record Official record
Conditions
Breast Cancer
Interventions
neratinib, placebo
Drug · Other
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
185
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 147 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 23, 2026, 7:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

NCT03698019
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
816
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 512 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Completed Not applicable Interventional

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors

NCT01453452
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Pain, Psychosocial Effects of Cancer and Its Treatment, Weight Changes
Interventions
behavioral dietary intervention, exercise intervention, counseling intervention, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
58
States / cities
Tucson, Arizona • Antioch, California • Fremont, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 23, 2026, 7:23 PM EDT
Active, not recruiting Not applicable Interventional

Sleep for Stroke Management and Recovery Trial

NCT03812653
View directory record Official record
Conditions
Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Interventions
CPAP
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,062 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
116
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Completed No phase listed Observational

Work Ability in Young Adult Cancer Survivors

NCT03148080
View directory record Official record
Conditions
Cancer Survivor
Interventions
Cognitive Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years to 34 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
326
States / cities
Fairbanks, Alaska • Fort Smith, Arkansas • Anaheim, California + 221 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Jul 23, 2026, 7:23 PM EDT
Recruiting Not applicable Interventional

Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee

NCT06216756
View directory record Official record
Conditions
Osteochondral Defect
Interventions
osteochondral transplant on the femoral condyle
Procedure
Lead sponsor
AlloSource
Industry
Eligibility
12 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 23, 2026, 7:23 PM EDT
Terminated Phase 3 Interventional

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

NCT00662597
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ASA404, Placebo, carboplatin, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
100
States / cities
Mobile, Alabama • Tucson, Arizona • Bentonville, Arkansas + 86 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Jul 23, 2026, 7:23 PM EDT
Terminated Phase 3 Interventional Results available

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT03028740
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Placebo, Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
204
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Jul 23, 2026, 7:23 PM EDT
Recruiting No phase listed Observational

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444
View directory record Official record
Conditions
Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Interventions
Guardant Reveal
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
33
States / cities
Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 23, 2026, 7:23 PM EDT
Suspended Phase 2Phase 3 Interventional

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NCT05050162
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
361
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 264 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Completed Phase 3 Interventional

A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)

NCT02511405
View directory record Official record
Conditions
Glioblastoma
Interventions
VB-111 + bevacizumab, Bevacizumab
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
48
States / cities
Birmingham, Alabama • Rogers, Arizona • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Jul 23, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

NCT01229943
View directory record Official record
Conditions
Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma
Interventions
Bevacizumab, Everolimus, Octreotide Acetate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
388
States / cities
Mobile, Alabama • Anaheim, California • Antioch, California + 272 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Jul 23, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

NCT01805076
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Triple-negative Breast Cancer
Interventions
Breast surgery, Magnetic resonance imaging, Mammography
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
179
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Antioch, California + 141 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Enrolling by invitation No phase listed Observational

Improving Risk Stratification of Emergency Department Patients With Acute Heart Failure

NCT06065761
View directory record Official record
Conditions
Heart Failure
Interventions
Comprehensive ED heart failure management tool
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
17,459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Antioch, California • Fremont, California • Fresno, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Active, not recruiting Phase 3 Interventional

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
865
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 553 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

NCT00915018
View directory record Official record
Conditions
Breast Cancer
Interventions
Neratinib, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
36
States / cities
Oxnard, California • Santa Rosa, California • Plainville, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Jul 23, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NCT03180294
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Bupropion 150 mg XL, Placebo
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
362
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Active, not recruiting Not applicable Interventional Results available

Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia

NCT03253848
View directory record Official record
Conditions
Acute Promyelocytic Leukemia With PML-RARA, t(15;17)
Interventions
Simplified Patient Care Strategy, Laboratory Biomarker Analysis
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
282
States / cities
Fairbanks, Alaska • Anaheim, California • Antioch, California + 218 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

NCT01945775
View directory record Official record
Conditions
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
talazoparib, Physician's-Choice
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
207
States / cities
Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jul 23, 2026, 7:23 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

NCT02196181
View directory record Official record
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trametinib Dimethyl Sulfoxide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
753
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 465 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

NCT00644228
View directory record Official record
Conditions
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
496
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 337 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

NCT01274338
View directory record Official record
Conditions
Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
1,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
929
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 581 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 7:23 PM EDT
Recruiting Phase 3 Interventional

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NCT06580314
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Biological · Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
658
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 447 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 23, 2026, 7:23 PM EDT